B. Riley Wealth Advisors’s Axsome Therapeutics AXSM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-2,473
Closed -$300K 1036
2025
Q3
$300K Buy
2,473
+2
+0.1% +$225 0.01% 729
2025
Q2
$258K Buy
+2,471
New +$262K 0.01% 776
2023
Q3
Sell
-3,347
Closed -$241K 1474
2023
Q2
$241K Buy
+3,347
New +$247K 0.01% 1248
2023
Q1
Sell
-3,361
Closed -$259K 1527
2022
Q4
$259K Buy
+3,361
New +$201K 0.01% 1111
2021
Q3
Sell
-4,147
Closed -$280K 1415
2021
Q2
$280K Buy
+4,147
New +$249K 0.01% 1056
2020
Q3
Sell
-6,450
Closed -$531K 948
2020
Q2
$531K Buy
+6,450
New +$496K 0.04% 441

Other funds holding AXSM

B. Riley Wealth Advisors's AXSM Position: Q4 2025 in Review

B. Riley Wealth Advisors sold out of Axsome Therapeutics (AXSM) in Q4 2025, closing a stake of 2,473 shares — an estimated $300K sold.

B. Riley Wealth Advisors first reported a position in AXSM in Q2 2020 and held it in 6 quarters. The position peaked at $531K in Q2 2020. 398 funds tracked by Wall St. Rank hold AXSM as of Q4 2025.

  • B. Riley Wealth Advisors reported no remaining Axsome Therapeutics position as of Q4 2025 after selling out during the quarter.
  • B. Riley Wealth Advisors sold 2,473 Axsome Therapeutics shares in Q4 2025, an estimated $300K.
  • B. Riley Wealth Advisors first reported a position in Axsome Therapeutics in Q2 2020 and held it in 6 quarters.
  • B. Riley Wealth Advisors's Axsome Therapeutics position peaked at $531K in Q2 2020.
  • 398 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q4 2025.

Based on B. Riley Wealth Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.